Pieris Pharmaceuticals Probability of Future Stock Price Finishing Over 16.92
| PIRSDelisted Stock | USD 13.60 1.41 9.39% |
Pieris |
Pieris Pharmaceuticals Target Price Odds to finish over 16.92
The tendency of Pieris Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 16.92 or more in 90 days |
| 13.60 | 90 days | 16.92 | about 22.66 |
Based on a normal probability distribution, the odds of Pieris Pharmaceuticals to move over $ 16.92 or more in 90 days from now is about 22.66 (This Pieris Pharmaceuticals probability density function shows the probability of Pieris Stock to fall within a particular range of prices over 90 days) . Probability of Pieris Pharmaceuticals price to stay between its current price of $ 13.60 and $ 16.92 at the end of the 90-day period is about 77.32 .
Given the investment horizon of 90 days Pieris Pharmaceuticals has a beta of -0.0617 indicating as returns on the benchmark increase, returns on holding Pieris Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Pieris Pharmaceuticals is likely to outperform the market. Additionally Pieris Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Pieris Pharmaceuticals Price Density |
| Price |
Predictive Modules for Pieris Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pieris Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pieris Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pieris Pharmaceuticals is not an exception. The market had few large corrections towards the Pieris Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pieris Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pieris Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.31 | |
β | Beta against Dow Jones | -0.06 | |
σ | Overall volatility | 0.56 | |
Ir | Information ratio | -0.12 |
Pieris Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pieris Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pieris Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pieris Pharmaceuticals is now traded under the symbol PVLA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Pieris Pharmaceuticals is not yet fully synchronised with the market data | |
| Pieris Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pieris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M). | |
| Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Latest headline from globenewswire.com: Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of 78.9 Million |
Pieris Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pieris Stock often depends not only on the future outlook of the current and potential Pieris Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pieris Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 26.4 M |
Pieris Pharmaceuticals Technical Analysis
Pieris Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Pieris Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Pieris Pharmaceuticals. In general, you should focus on analyzing Pieris Stock price patterns and their correlations with different microeconomic environments and drivers.
Pieris Pharmaceuticals Predictive Forecast Models
Pieris Pharmaceuticals' time-series forecasting models is one of many Pieris Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Pieris Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Pieris Pharmaceuticals
Checking the ongoing alerts about Pieris Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Pieris Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Pieris Pharmaceuticals is now traded under the symbol PVLA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Pieris Pharmaceuticals is not yet fully synchronised with the market data | |
| Pieris Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pieris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M). | |
| Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Latest headline from globenewswire.com: Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of 78.9 Million |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Pieris Stock
If you are still planning to invest in Pieris Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pieris Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |